Weiss Ratings Reiterates “Sell (D-)” Rating for 111 (NASDAQ:YI)

111 (NASDAQ:YI)‘s stock had its “sell (d-)” rating reiterated by equities research analysts at Weiss Ratings in a research report issued on Saturday,Weiss Ratings reports.

111 Price Performance

NASDAQ:YI opened at $10.49 on Friday. The firm has a 50-day moving average of $7.22 and a two-hundred day moving average of $7.33. The stock has a market cap of $89.71 million, a P/E ratio of -2.62 and a beta of 0.46. 111 has a 1-year low of $4.15 and a 1-year high of $14.10.

111 (NASDAQ:YI) last posted its quarterly earnings data on Thursday, March 20th. The company reported ($0.04) earnings per share for the quarter. The business had revenue of $527.14 million for the quarter.

Hedge Funds Weigh In On 111

Several large investors have recently modified their holdings of the stock. FIL Ltd bought a new position in shares of 111 during the fourth quarter worth about $450,000. JPMorgan Chase & Co. lifted its position in shares of 111 by 43,619.9% during the fourth quarter. JPMorgan Chase & Co. now owns 306,039 shares of the company’s stock worth $191,000 after purchasing an additional 305,339 shares during the last quarter. Finally, Napean Trading & Investment Co Singapore PTE Ltd bought a new position in shares of 111 during the fourth quarter worth about $245,000. Institutional investors own 21.32% of the company’s stock.

About 111

111, Inc engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies.